183 related articles for article (PubMed ID: 19402868)
21. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
22. [Cabergoline in hyperprolactinemia and valvular heart disease].
Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
[TBL] [Abstract][Full Text] [Related]
23. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
25. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment.
Luedde M; Helmke B; Katus HA; Frey N
Int J Cardiol; 2009 Apr; 133(3):e97-8. PubMed ID: 18191474
[TBL] [Abstract][Full Text] [Related]
26. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
27. [Complications of treatment of prolactinoma by dopamine agonists].
Astaf'eva LI; Kadashev BA; Kutin MA; Kalinin PL
Zh Vopr Neirokhir Im N N Burdenko; 2011; 75(2):41-50; discussion 50. PubMed ID: 21793295
[TBL] [Abstract][Full Text] [Related]
28. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
29. Cabergoline and mitral regurgitation.
Delgrange E
N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
[No Abstract] [Full Text] [Related]
30. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
31. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
Balarini Lima GA; Machado Ede O; Dos Santos Silva CM; Filho PN; Gadelha MR
Pituitary; 2008; 11(3):287-92. PubMed ID: 17570067
[TBL] [Abstract][Full Text] [Related]
32. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
33. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
Dhanwal DK; Sharma AK
Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
[TBL] [Abstract][Full Text] [Related]
34. Benfluorex-induced severe primary tricuspid and mitral regurgitation requiring a double-valve replacement.
Eugène M; Bruneval P; Bonnet N; Attias D
Eur J Cardiothorac Surg; 2018 Jul; 54(1):195. PubMed ID: 29444226
[No Abstract] [Full Text] [Related]
35. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Freeman B; Levy W; Gorman JM
J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
[No Abstract] [Full Text] [Related]
36. Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma.
Doğan BA; Arduc A; Tuna MM; Berker D; Demirci N; Demirtaş S; Çiçekcioğlu H; Güler S
Endocr Metab Immune Disord Drug Targets; 2016; 16(1):47-55. PubMed ID: 26924497
[TBL] [Abstract][Full Text] [Related]
37. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
38. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
[TBL] [Abstract][Full Text] [Related]
39. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
[TBL] [Abstract][Full Text] [Related]
40. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
